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We conducted a phase I/II study investigating synchronous chemoradiotherapy with mitomycin C and infusional 5-fluorouracil (5-FU)
in muscle invasive bladder cancer. Early dose escalation results were previously published. We report the long-term toxicity and
efficacy results with the optimised regimen. Patients with muscle invasive bladder cancer with glomerular filtration rate 425mlmin
 1
were eligible. Mitomycin (12mgm
 2 on day 1 only) and infusional 5-FU (500mgm
 2day
 1) for 5 days were administered during
weeks 1 and 4 of radiotherapy of 55Gy in 20 fractions. A total of 41 patients were enrolled, median age was 68 years, 33 were male
and eight female patients. Out of the 41 patients, 20 (49%) had hydronephrosis at presentation and 25 (62%) had T3b or T4 disease.
Four patients experienced Grade III thrombocytopenia and three patients had Grade III neutropenia. There were no episodes of
febrile neutropenia. Four patients experienced Grade III diarrhoea and 1 Grade III urgency and dysuria. Six patients did not undergo
cystoscopic evaluation due to early metastatic spread although there was no clinical suggestion of bladder failure. In all, out of 35
evaluable patients, 25 (71%) had macroscopic complete response at 3-month cystoscopy, and biopsy confirmed in 24 out of 25. A
total of 16 (39%) patients remain alive with a median follow-up of 50.7 (range 23.5–68.8) months, 14 with a functioning bladder with
no reported long-term treatment-related bladder or bowel toxicity. Five out of 41 patients have undergone salvage cystectomy: two
for persistent CIS, two T1 and one muscle invasive recurrence. Four patients have received intravesical chemotherapy, of whom two
remain alive with a functioning bladder. Overall 12-, 24- and 60-month (m) survival rates were 68, 49 and 36%. Local and distant
progression free rates were 82 and 86% at 12-m and 79 and 75% at 24-m. Organ preservation using multimodality therapy is feasible
and safe, even in patients with poor renal reserve, and does not compromise salvage therapies. A national phase III trial BC2001
(www.bc2001.org.uk) exploring the effects of synchronous chemoradiotherapy with this regimen is currently recruiting.
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The optimum management strategy for control of locally advanced
bladder cancer remains to be determined. Surgical removal of the
bladder may attain local control but 20-30% of patients may
develop a local relapse (Hall and Dinney, 1996, Smith et al, 1997)
and all will need either reconstructive bladder surgery or an ileal
diversion. Improved surgical techniques have improved quality of
life after cystectomy; however, even continent urinary diversion
with orthotopic lower urinary tract reconstruction cannot
substitute for the patient’s original bladder. Radical radiotherapy
is commonly used as an alternative to surgery especially in the UK.
For every patient undergoing surgery in the UK there are two
patients receiving radiation treatment (BAUS 2000). This approach
suffers from a relatively high rate of incomplete response or local
recurrence (up to 50%) with salvage cystectomy being used for
failures (Parker and Huddart, 1996; Cooke et al, 2000).
ROLE OF SYNCHRONOUS CHEMORADIOTHERAPY
There are indications from other primary sites that synchronous
chemoradiotherapy may produce local control with or without
survival advantages (Chan et al, 1993; Pritchard and Anthony,
1996; UKCCCR working party, 1996; Al-Sarraf et al, 1997; Haffty
et al, 1997). A variety of phase II studies have investigated the
efficacy and toxicity of this approach in bladder cancer generally
with encouraging results (Hussain and James, 2002). Ro ¨del et al
(2002a) recently described a large experience with organ-sparing
treatment of invasive bladder cancer, documenting long-term
outcome of 415 patients treated over a 20-year time period
showing promising results. Zietman et al (1993) and Shipley et al
(1985, 2002) from Massachusetts General Hospital and Sauer et al
(1998) from Erlangen have reported promising results with organ
preservation strategies over the last decade that offered hope and
an option for bladder preservation in a significant proportion of
patients who currently undergo cystectomy.
EVIDENCE FOR ORGAN PRESERVATION
We have previously reported results from our single centre phase
I/II study investigating the role of synchronous chemoradio-
therapy using mitomycin C and infusional 5-flourouracil (5-FU) in
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lmuscle invasive bladder cancer (Hussain et al, 2001). We now
report the final results of long-term toxicity and efficacy of patients
receiving the optimised regimen of 5 days 5-FU infusion with
mitomycin C. Currently, the only randomised evidence for organ
preservation in bladder cancer comes from a small trial by the
national cancer institute of Canada (Coppin et al, 1996). This study
randomised 99 patients to receive cisplatin 100mgm
 2 with
radiotherapy or radiotherapy alone at a dose of 40Gy followed by
elective cystectomy or further radiotherapy. The chemoradiother-
apy arm showed statistically nonsignificant improvements in
complete response rate to radiotherapy. Significant differences
were seen in the pattern of relapse. The use of cisplatin in bladder
cancer is limited by its renal toxicity as significant proportions of
patients have impaired renal function with hydronephrosis and
additionally administration may require in-patient stay and
hydration. We evaluated a combination of 5-FU, mitomycin C
and radiotherapy in a phase I dose escalation study using a similar
schedule adapted from that used in UKCCCR anal carcinoma study
(UKCCCR working party, 1996). 5-Flourouracil is systemically
active in bladder cancer (Carter and Wasserman, 1975; Logothetis
et al, 1991; Huan et al, 1995). Mitomycin C is of value as a
radiosensitiser (UKCCCR working party, 1996). Low-dose 5-FU
and mitomycin C were tested in a small phase II study of
predominantly T3/T4 patients and achieved a 74% clinical
complete response (CR) rate and long-term survival of 54%
(Rotman et al, 1990). The radiation treatment consisted of 4000–
4500rad over 4.5–5 weeks to pelvis and 2000–2500rad boost.
PATIENTS AND METHODS
Patients with histologically confirmed muscle invasive primary
transitional cell carcinoma of the bladder (T2-4a N0/NX M0) were
eligible for the study. Other entry criteria included ECOG
performance status 0–2, written informed consent, no concomi-
tant or previous malignancy likely to interfere with the protocol
treatment or assessment, leucocytes 44 10
9l
 1, platelets
4100 10
9l
 1, glomerular filtration rate (GFR), calculated by
Cockcroft formula, 425mlmin
 1, AST, ALP o1.5 the upper
limit of normal range. Prior to therapy, all patients underwent
physical examination, haematological, renal and biochemical
profile examination, CT scan of abdomen and pelvis, chest X-ray
and examination under anaesthetic plus cystoscopic resection of
tumour and biopsy. The TNM classification (1997) was used for
staging purposes.
Study design
This study had Local Research Ethics Approval and started
enrolling patients in June 1998. The study was a combined phase I/
II study. The early dose escalation part of this study has previously
been reported (Hussain et al, 2001). The primary end point of the
phase II portion of the study was pathological response in the
bladder at 3 months with secondary end points of toxicity, time to
progression and overall survival. Toxicity was assessed using the
NCI grading system.
Treatment
Treatment comprised chemotherapy and radiotherapy synchro-
nously, with chemotherapy starting 1h earlier than the commence-
ment of radiotherapy on day 1 of the start of treatment.
Radiotherapy
All patients were planned with the bladder empty to keep the
clinical target volume as small as possible. The planning target
volume (according to the ICRU 50 conventions) encompassed the
normal bladder with a margin of 1.5cm, and assessable tumour
plus a margin of 2cm. The anterior margin was also reduced to
1.5cm where a larger margin would lie within the os pubis.
Treatment was given to a single planning target volume. The
patients were catheterised and 30ml contrast medium introduced.
Initial localisation films were taken on the simulator and fiduciary
marks made before transfer to the CT scanner. CT images were
transferred electronically to the radiotherapy planning system for
mark-up. All patients were planned using computerised tomo-
graphic techniques on the central slice of the planning target
volume. Typical field arrangements were an anterior open field
and two wedged oblique posterolateral fields. Radiotherapy dose
was 55Gy in 20 fractions over 4 weeks, prescribed at the field
intersection with less than 75% variation across the planning
target volume. Changes in fractionation due to machine break-
down, etc., were handled according to the recommendations issued
by the Royal College of Radiologists on treatment delays: the
preferred options being transfer to another machine or twice daily
treatment with a 6h gap thereby keeping the total duration of
radiotherapy constant (www.rcr.ac.uk).
Chemotherapy
The chemotherapy comprised single dose of mitomycin C and 5-
FU as a continuous infusion. Concurrent chemotherapy with 5-FU
500mgm
 224h
 1 was given during fractions 1–5 and 16–20 of
radiotherapy treatment (total 10 days therapy). Mitomycin- C was
given at a dose of 12mgm
 2 as a single bolus on day 1 of
radiotherapy treatment. Chemotherapy was planned in an out-
patient setting via a peripherally inserted central catheter (PICC)
line.
Response Assessment
All patients were scheduled for rigid check cystoscopy with tumour
bed biopsy at 3 months post-treatment. A post-treatment CT scan
was performed prior to cystoscopy to check for local or distant
recurrence. Patients with metastatic spread did not undergo check
cystoscopy, although local pelvic spread could be assessed on the
scan. Subsequent cystoscopies were carried out at 6 months, then 6
monthly, with biopsy only if clinically indicated.
Statistical considerations
All patients receiving treatment were included in the toxicity and
survival analysis. Data were analysed when all alive patients had
been followed for a minimum of 2 years (November, 2003).
Response rates and toxicity data were analysed with simple
descriptive statistics. Survival was calculated from date of
diagnosis to date of death for any cause, or censor date for alive
patients. Time to progression analysis censored patients at the
time of death if they died without clinical evidence of progression.
Survival and progression free estimates were calculated according
to the method of Kaplan and Meier (1958).
RESULTS
Patient characteristics
A total of 41 patients entered the trial from March 1998 to August
2001 of whom 20 were in the phase I dose escalation portion of the
study. Median age was 68 (range 58–79) years, with 33 male and
eight female patients (Table 1).
Toxicity
Toxicity was mild to moderate. A total of 35 patients (85%)
received the full planned dose of 10 days of concurrent
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lchemotherapy and all patients received the planned radiotherapy
(Table 1). One patient declined to receive the second infusion
because of grade 2 nausea, two patients received a 25% dose
reduction during the second infusion due to GI toxicity and in two
cases the second infusion was interrupted after 3 days, one due to
grade 3 thrombocytopenia and one due to venous access
complications. In one case, the second infusion was not instituted
because of Grade III thrombocytopenia as per the protocol
(Table 2).
Haematological toxicity The treatment was well tolerated with
little in the way of haematological toxicity. On this regimen, four
patients suffered from Grade III thrombocytopenia and three
patients had Grade III neutropenia. There was no grade IV
haematological toxicity and no episode of febrile neutropenia or
neutropenic sepsis.
Nonhaematological toxicity Cystitis and diarrhoea were the main
nonhaematological toxicity encountered during the course of
synchronous chemoradiation treatment. The treatment was well
tolerated with four patients encountering Grade III diarrhoea and
one patient experiencing Grade III urgency and dysuria.
Chemotherapy in an outpatient setting
Chemotherapy was given in an outpatient setting via a PICC line in
33 patients, four patients opted for outpatient therapy but required
in-patient treatment because of poor venous access and four
patients opted for in-patient treatment.
Response to therapy
Of the 41 patients, 35 were eligible for local response assessment.
Six of the 41 patients did not undergo cystoscopic evaluation due
to early metastatic spread although there was no clinical
suggestion of bladder failure. Of the 35 patients, 25 (71%) had
macroscopic complete response at 3-month cystoscopy, confirmed
by tumour bed biopsy in 24 out of 25 (intention to treat complete
response rate 25 out of 41 (61%)). Two patients had residual
carcinoma in situ, and one had T1 disease at cystoscopy with no
muscle invasion and they underwent salvage cystectomy. Two
patients with residual superficial carcinoma were treated with
intravesical chemotherapy. The remaining five had persistent
muscle invasive disease (Figure 1). At a median follow-up of 51
months, 16 patients remain alive, 14 of them with functioning
bladder. Of these sixteen alive patients, 12 have no signs of local
progression, two relapsed with superficial disease and had
intravesical chemotherapy, and two underwent salvage cystectomy
for invasive recurrence 36 and 48 months post-treatment,
respectively. In total, five out of 41 patients underwent salvage
cystectomy. Seven patients with complete response in the bladder
went on to develop distant metastases: one in the para-aortic
lymph nodes that was treated successfully with CMV chemother-
apy and local irradiation (this patient’s bladder has remained free
of disease throughout); in the second case, also with a durable local
complete response, the patient developed brain metastases and
died. A further five patients developed visceral metastasis and were
treated with chemotherapy. Patterns of relapse are detailed in
Tables 3 and 4.
Survival and time to progression analyses
Of the 41 patients, 25 had died by the time of analysis with a
median follow-up of 50.7 months (range 23.5–68.8 months) for the
Table 1 Patient characteristics
Patients (%) N¼41
Age (years)
Median 68
Range 58–77
Sex
Male 33 80%
Female 08 20%
Stage
T2 10 24%
T3a 06 14%
T3b 14 34%
T4 11 28%
Grade
2 10 24%
3 31 76%
Hydronephrosis
Yes 21 51%
No 20 49%
GFR
o50mlmin
 1 17 32%
Performance status
0 25 61%
1 11 27%
2 5 12%
Completing planned treatment
Radiotherapy 41 100%
Chemotherapy 35 85%
Table 2 Toxicity (maximum toxicity recorded)
Toxicity Patients (%) N¼41
Diarrhoea
Grade 1 16 (39%)
Grade 2 13 (32%)
Grade 3 4 (10%)
Cystitis dysuria/urgency
Grade 1 15 (36%)
Grade 2 7 (17%)
Grade 3 1 (2%)
Thrombocytopenia
Grade 1 21 (51%)
Grade 2 7 (17%)
Grade 3 4 (10%)
Neutropenia
Grade 1 20 (49%)
Grade 2 9 (22%)
Grade 3 3 (7%)
41 patients 
35 evaluable 
25 complete response  2 CIS 
Cystectomy
3 T1  5 persistent disease 
1 cystectomy 2 intravesical 
chemotherapy
6 nonevaluable 
16 patients alive (14 with retained bladder) at a median follow-up of 50.7 months 
Figure 1 Response to therapy.
Chemoradiotherapy for locally advanced bladder cancer
SA Hussain et al
2108
British Journal of Cancer (2004) 90(11), 2106–2111 & 2004 Cancer Research UK
C
l
i
n
i
c
a
l16 alive patients. Overall, 12-, 24- and 60-month survival rates were
68% (95% CI: 54%–83%), 49% (CI: 33%–64%) and 36% (CI:
20%–52%) (Figure 2). Of the 25 deaths, 15 were bladder cancer
specific. The 12- and 24-month cause-specific survival was 77%
(95% CI: 64–90%) and 68% (95% CI: 53–83%), respectively. Six
patients were not evaluable for local progression and five were not
evaluable for distant progression because of early death or distant
progression, without any symptoms of local relapse or progression
and did not undergo cystoscopy for local control assessment. Of
the 35 patients, 11 had local progression and 10 of 36 patients had
distant progression confirmed at the time of analysis. In all, 12 and
11 patients died without local or distant progression, respectively.
These patients were censored and included in the analysis being at
risk of progression up to their death (Tables 3 and 4). Local and
distant progression free rates were 82% (CI: 70–95%) and 86% (CI:
75–97%) at 12 months and 79% (CI: 65–93%) and 75% (CI: 60–
90%) at 24 months, respectively (Figures 3 and 4).
Renal function
The renal functions remained stable or improved while on
treatment. No patient suffered a clinically significant drop in renal
function as shown in Figure 5.
Table 3 Survival
Local progression Distant progression
No Yes No Yes
Status
Alive 12 4 15 1
Dead 12 7 11 9
Total 24 11 26 10
Table 4 Pattern of relapse
DP
No Yes Total
LP
No 17 7 24
Yes 9 2 11
Total 26 9 35
Figure 2 Overall survival.
Figure 3 Time to local progression.
Figure 4 Time to distant progression.
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Figure 5 Effect of treatment on renal function.
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lDISCUSSION
The initial phase I study showed that the addition of infusional 5-
FU plus mitomycin C to full-dose radical radiotherapy is safe and
feasible in patients with locally advanced bladder cancer (Hussain
et al, 2001). Dose escalation from 5 days to 7 days, however,
resulted in increased toxicity and more frequent dose modifica-
tions in both chemotherapy and radiotherapy particularly in the
second half of the treatment schedule. Treatment in most cases was
completed as an outpatient using an infusion pump and PICC line
avoiding significant use of in-patient resources and increasing
patient convenience. The 5-day infusion schedule was selected as
the basis for the phase II study and this trial continued recruitment
until the commencement of the national phase III trial, BC2001 in
August 2001 (www.bc2001.org.uk), which is funded by Cancer
Research UK and supported by National Cancer Research
Network. The high pathological response rate contrasts with that
reported in radiotherapy series and suggests a significant radio-
sensitising effect. The response rate is consistent with that seen in
previous chemoradiotherapy series and in particular is consistent
with the chemoradiotherapy arm of the randomised study reported
by Coppin et al (1996). Furthermore, the response rate quoted in
that study for radiotherapy alone was 52%. In addition, in our
group, a number of patients had macroscopically normal bladders
at follow-up but biopsy confirmed microscopic persistent disease.
Thus the usual cystoscopic follow-up with biopsy reserved for
patients with visible disease may overestimate reported response
rates. Patients receiving this regimen had particularly high rates of
local control with a 1-year local progression free rate of 82 and
79% at 2 years. It is worth mentioning that in our series, 20 out of
41 patients presented with hydronephrosis, a poor prognostic
factor for patients with bladder cancer and 17 out of 41 patients
had a GFR o50mlmin
 1, which would have excluded them from a
cisplatin-containing regimen. Additionally, in this study popula-
tion, 76% of patients had T3 or T4 disease and 76% had poorly
differentiated (G3) disease. Overall, 12-month survival was 68%,
24-month survival was 49% and 60-month survival was 36%. A
number of patients (seven out of 24) developed metastatic disease
in the absence of local failure – of 19 deaths, 12 patients were still
disease free in the bladder. This suggests that the reason for
treatment failure was the presence of occult metastatic
disease at the time of treatment, rather than failure to control
the primary tumour leading to local and distant failure. This
highlights the need for more effective systemic therapies for the
disease in addition to methods of improving local control. The US
Intergroup study (Grossman et al, 2003) and a large meta-analysis
(Advanced Bladder Cancer Meta-analysis Collaboration, 2003)
have both recently reported positive results with the use of neo-
adjuvant chemotherapy, which should be regarded as the standard
of care. Most treatment-related effects settled down over the weeks
after completion of therapy. At the median follow-up of 50.7
months, we have not seen any late bowel or bladder toxicity. Five
patients proceeded to salvage cystectomy, three for persistent but
downstaged disease (one from T3 to T1, and two from T2 to CIS)
and two for recurrent disease. There was no evidence that the
addition of chemotherapy to radiotherapy had compromised
subsequent surgery, although clearly numbers are too small to
draw definite conclusions. Patients with persistent muscle
invasive disease did not undergo cystectomy secondary to other
comorbid conditions that precluded them from the option of
salvage cystectomy. All the patients who were fit for surgery
at the time of recurrence were offered the option of salvage
cystectomy.
Overall, this regimen has encouraging activity with acceptable
toxicity in a poor prognosis group of patients many of whom would
not have been fit for platinum-based chemotherapy. The schedule
can be given as an outpatient in most cases. Response rates are
comparable to those reported in previous chemoradiotherapy
series, including the one randomised comparison with radio-
therapy. The outcomes for large locally advanced bladder tumours
with extravesical extension are poor regardless of the treatment
modality used (Bassi et al, 1999; Gschwend et al, 2002). A majority
of patients with complete pathological response retain their
bladders free from invasive relapse, while about one-quarter will
develop superficial recurrence. This may be managed in the
standard fashion with transurethral resection of the bladder tumour
and intravesical therapies (Zietman et al, 2001; Ro ¨del et al, 2002b).
The national randomised phase III trial, BC2001 launched in
August 2001, will further define the role of synchronous
chemoradiotherapy in muscle invasive bladder cancer.
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